Beijing Health Guard Completes Series C Financing to Support Phase III Clinical Trials and Commercial Production of Core HPV vaccines

After two consecutive rounds at a premium price, Beijing Health Guard Biotechnology Inc. (thereafter, the Company) has recently completed a Series C financing, with the 33 million newly issued shares from its private placement starting to list and made available for trading on the National Equities Exchange and Quotations (NEEQ) on Christmas Day. Based on the price of the Company’s shares at the open on the NEEQ, market cap of the Company has surpassed CNY 4 billion.

This round has raised CNY 650 million for the Company. Proceeds from the series C will be used to fund phase III clinical trials of the trivalent HPV vaccine (targeting HPV 16/18/58) and nonavalent HPV vaccine (targeting HPV 6/11/16/18/31/33/45/52/58), construction of a commercial production plant for HPV vaccines, and preclinical R&D activities

The success of series C financing will effectively relieve the Company of  financial pressure imposed by funding shortage. With an extended financial runway, the Company will ensure that phase III clinical trials of the trivalent and nonavalent HPV move ahead smoothly, construction of the Company's commercial production plant will go ahead as planned, and more R&D projects will be advanced to unlock the full potential of the Company’s platform and technology.

The Company also plans for a pre-IPO round following its series C financing, with the aim of securing funds for future R&D efforts and plant construction, as well as preparing itself for a debut on the financial market.